AQR Capital Management
NVO

AQR Capital Management’s Novo Nordisk NVO Stock Holding History

AQR Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.66M Buy
181,129
+39,719
+28% +$1.88M ﹤0.01% 1566
2025
Q4 		$7.19M Buy
141,410
+17,615
+14% +$901K ﹤0.01% 1368
2025
Q3 		$6.87M Sell
123,795
-1,655
-1% -$96.9K ﹤0.01% 1272
2025
Q2 		$8.66M Buy
125,450
+63,351
+102% +$4.31M 0.01% 1024
2025
Q1 		$4.31M Buy
62,099
+10,758
+21% +$889K ﹤0.01% 1202
2024
Q4 		$4.42M Buy
51,341
+353
+0.7% +$38.2K 0.01% 1158
2024
Q3 		$6.07M Buy
50,988
+33,824
+197% +$4.51M 0.01% 969
2024
Q2 		$2.45M Buy
17,164
+9,012
+111% +$1.19M ﹤0.01% 1368
2024
Q1 		$1.05M Buy
8,152
+2,990
+58% +$356K ﹤0.01% 1669
2023
Q4 		$534K Sell
5,162
-133
-3% -$13.2K ﹤0.01% 1850
2023
Q3 		$482K Buy
+5,295
New +$466K ﹤0.01% 1859

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

AQR Capital Management's NVO Position: Q1 2026 in Review

AQR Capital Management increased its Novo Nordisk (NVO) stake by 28% in Q1 2026, buying an estimated $1.88M and bringing the position to 181,129 shares worth $6.66M. The position accounts for ﹤0.01% of the portfolio, ranked #1566.

AQR Capital Management first reported a position in NVO in Q3 2023 and has held it in 11 quarters since. The position peaked at $8.66M in Q2 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • AQR Capital Management held 181,129 shares of Novo Nordisk worth $6.66M as of Q1 2026.
  • AQR Capital Management bought 39,719 Novo Nordisk shares in Q1 2026, an estimated $1.88M.
  • Novo Nordisk made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #1566 holding.
  • AQR Capital Management first reported a position in Novo Nordisk in Q3 2023 and has held it in 11 quarters since.
  • AQR Capital Management's Novo Nordisk position peaked at $8.66M in Q2 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.